Ta-Chuan Tuan

Taipei Veterans General Hospital, T’ai-pei, Taipei, Taiwan

Are you Ta-Chuan Tuan?

Claim your profile

Publications (85)318.3 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: The risk of acute myocardial infarction (AMI) in patients with atrial fibrillation (AF) having a CHA2DS2-VASc score of 0 (for males) or 1 (for females) has not been previously investigated.
    Heart rhythm: the official journal of the Heart Rhythm Society 08/2014; · 4.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The characteristics of endocardial electrograms needed to detect the overlying abnormal epicardial substrates in arrhythmogenic right ventricular cardiomyopathy with epicardial ventricular tachycardia remain unclear. The current study investigated which of the endocardial electrogram characteristics could predict the overlying abnormal epicardial substrates.
    Journal of Cardiovascular Electrophysiology 07/2014; · 3.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background:Although the link between sleep-disordered breathing (SDB) and atrial fibrillation (AF) has been reported, a population-based longitudinal cohort study was lacking. The goal of the present study was to investigate the AF risk carried by SDB, using the National Health Insurance Research Database in Taiwan.Methods and Results:From 2000 to 2001, a total of 579,521 patients who had no history of cardiac arrhythmias or significant comorbidities were identified. Among them, 4,082 subjects with the diagnosis of SDB were selected as the study group, and the remaining 575,439 subjects constituted the control group. The study endpoint was the occurrence of new-onset AF. During a follow-up of 9.2±2.0 years, there were 4,023 patients (0.7%) experiencing new-onset AF. The occurrence rate of AF was higher in patients with SDB compared to those without it (1.3% vs. 0.7%, P<0.001). The AF incidences were 1.38 and 0.76 per 1,000 person-years for patients with and without SDB, respectively. After anadjustment for age and sex, SDB was a significant risk factor of AF with a hazard ratio of 1.536. The AF risk increased with increasing clinical severity of SDB, represented by the requirement of continuous positive airway pressure use.Conclusions:SDB itself, without the coexistence of other systemic diseases, was a risk factor of AF.
    Circulation journal : official journal of the Japanese Circulation Society. 07/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Renal dysfunction is a significant risk factor of ischemic stroke in atrial fibrillation (AF). However, the incidence of ischemic stroke and how to predict its occurrence amongst AF patients with end-stage renal disease (ESRD) are unclear.
    Heart rhythm: the official journal of the Heart Rhythm Society 06/2014; · 4.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Radiofrequency catheter ablation (RFCA) is an effective therapeutic strategy in eliminating drug-refractory idiopathic right ventricular outflow tract ventricular arrhythmias (RVOT VAs). It remains unclear what factors influence early and late VA recurrences after ablation.
    Heart rhythm: the official journal of the Heart Rhythm Society 06/2014; · 4.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Signal averaged electrocardiogram (SAECG) is a specific and non-invasive tool useful for arrhythmogenic right ventricular cardiomyopathy (ARVC) diagnosis. However, its role in risk stratification of patients with ARVC remains largely undefined. Sixty-four patients fulfilling Task Force ARVC criteria (mean age: 47±14years-old, 56% male, 50% definite ARVC) were enrolled. The baseline demographic, electrocardiographic, structural, and electrophysiological characteristics were collected. Patients with SAECG fulfilling all 3 Task Force criteria (3+ SAECG) were categorized into group 1, and those fulfilled 2 or less criterion were categorized into group 2. The study endpoints were unstable ventricular arrhythmia (VA), device detectable sustained fast VA (cycle lengths <240ms) and cardiovascular death. During a mean follow-up of 21±20months, 15 primary endpoints including 12 unstable VAs and 3 device-detected fast VAs were met. One patient died of electrical storm, and one patient underwent heart transplantation. The presence of 3+ SAECG predicted malignant events in all patients with definite and non-definite ARVC (p<0.01, OR=30.5, 95% CI=2.5-373.7) and in patients with definite ARVC alone (p=0.03, OR=11.1, 95% CI=1.3-93.9). Patients diagnosed with non-definite ARVC without 3+ SAECG were free from malignant events. SAECG fulfilling all 3 Task Force criteria was an independent risk predictor of malignant events in ARVC patients. SAECG may play a valuable role in ARVC risk stratification.
    International journal of cardiology 04/2014; · 6.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Renal dysfunction is a significant risk factor of ischemic stroke in atrial fibrillation (AF). However, the incidence of ischemic stroke and how to predict its occurrence amongst AF patients with end-stage renal disease (ESRD) are unclear. Objective The goal of the present study was to compare the CHADS2 and CHA2DS2-VASc scores for stroke risk stratification in AF patients with ESRD. Methods A total of 10,999 AF patients with ESRD undergoing renal replacement therapy who were not receiving oral anticoagulants or antiplatelet agents were identified from Taiwan’s National Health Insurance Research Database. The study endpoint was occurrence of ischemic stroke. Results The median (IQR) CHADS2 and CHA2DS2-VASc scores for the study cohort were 3 (2-5) and 5 (4-7), respectively. During the follow-up, 1,217 patients (11.7%) experienced ischemic stroke, with an incidence rate of 6.9 per 100 person-years. In Cox regression models, the CHADS2 and CHA2DS2-VASc scores were both significant predictors of ischemic stroke. C-indexes for CHADS2 and CHA2DS2-VASc were 0.608 and 0.682, respectively (p<0.001). CHA2DS2-VASc improved the net reclassification index by 4.8% compared with CHADS2 (p<0.0001). Among 1,409 patients with a CHADS2 score of 0 or 1, the CHA2DS2-VASc score ranged from 1 to 4, with event rates ranging from 2.1 to 4.7 per 100 person-years. Conclusions The CHA2DS2-VASc score was useful in predicting ischemic stroke in AF patients with ESRD undergoing dialysis, and was superior to CHADS2. The net clinical benefit balancing stroke reduction against major bleeding with anticoagulation in these high risk patients remains to be defined.
    Heart Rhythm. 01/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background A new risk model, the R2CHADS2 score, was proposed to be a powerful scoring scheme in predicting stroke or systemic embolism in atrial fibrillation (AF). The goal of the present study is to validate the usefulness of R2CHADS2 score among AF patients after catheter ablations. We also aimed to compare the accuracies of the CHA2DS2-VASc and R2CHADS2 scores for risk stratifications of thromboembolic (TE) events after ablation procedures. Methods We enrolled a total of 526 patients with AF who underwent catheter ablation. The clinical endpoint was the occurrence of TE events (ischemic stroke, transient ischemic attack, or other systemic embolisms) during the post-ablation follow-up. Results During a follow-up of 37.5+21.3 months, 14 patients (2.7%) experienced TE events. The R2CHADS2 score was an independent predictor of TE events in the multivariate analysis. Patients with a R2CHADS2 score of > 2 had a higher event rate compared to those with a score of 0 or 1 (0.5% versus 7.7%). The areas under the ROC curves of CHA2DS2-VASc and R2CHADS2 scores in predicting TE events were 0.832 and 0.872, respectively. The difference between these 2 curves did not reach statistical significance (p value = 0.338). In addition, the R2CHADS2 score did not improve net stroke risk reclassification over the CHA2DS2-VASc score (net reclassification improvement = -0.9%, p value = 0.948). Conclusions The R2CHADS2 and CHA2DS2-VASc scores could be used to predict TE events for AF patients receiving catheter ablations. The predictive accuracies of both scores were similar in this relatively small-sized cohort undergoing ablation.
    The Canadian journal of cardiology 01/2014; · 3.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Digoxin and related cardiac glycoside have been used for almost 100 years in atrial fibrillation (AF). However, recent 2 analyses of the “AFFIRM” trial showed non-consistent results about the risk of mortality associated with digoxin use. The goal of the present study is to investigate the relationship between digoxin and the risk of ischemic stroke and mortality in Asians. Methods This study used the “National Health Insurance Research Database” in Taiwan. A total of 4,781 AF patients who did not receive any antithrombotic therapy were selected as the study population. Among the study population, 829 subjects (17.3%) received the digoxin treatment. The risks of ischemic stroke and mortality of patients with or without digoxin use were compared. Results The use of digoxin was associated with an increased risk of clinical events with an adjusted hazard ratio of 1.41 (95% CI =1.17-1.70) for ischemic stroke and 1.21 (95% CI =1.01-1.44) for all-cause mortality. In the subgroup analysis based on the coexistence with heart failure or not, digoxin was a risk factor of adverse events for patients without heart failure, but not for those with heart failure (interaction p<0.001 for either endpoint). Among AF patients without heart failure, the use of beta-blockers was associated with better survival with an adjusted hazard ratio of 0.48 (95% CI = 0.34-0.68). Conclusions Digoxin should be avoided for AF patients without heart failure since it was associated with an increased risk of clinical events. Beta-blockers may be a better choice for controlling ventricular rate.
    The Canadian journal of cardiology 01/2014; · 3.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Radiofrequency catheter ablation (RFCA) is an effective therapeutic strategy in eliminating drug-refractory idiopathic right ventricular outflow tract ventricular arrhythmias (RVOT VAs). It remains unclear what factors influence early and late VA recurrences after ablation. Objectives The aim of our study was to elucidate the differences between early and late recurrences after acute successful RFCA of RVOT VAs in a long-term follow-up. Methods A total of 220 patients with acute successful RFCA of RVOT VAs were enrolled. Detailed clinical characteristics and assessments by non-invasive and invasive electrophysiological studies were explored to predict the overall, early (≤ 1 year), and late VA recurrences (>1 year). Results During a mean follow-up of 34.15±33.74 months, 45 of the 220 patients (20.5%) documented recurrence of RVOT VAs after initial RFCA. Of them, 26 (57.8%) recurrent VA showed similar morphology, and 19 (42.2%) were different. Patients with recurrent VAs were associated with higher incidence of hypertension, higher systolic BP, identification of foci by pacemapping alone, shorter earliest activation time, more RF pulses required, and VA originating from anterior free wall. Multivariate analysis demonstrated that mapping strategy and shorter earliest activation time preceding VA were associated with early recurrences (P<0.001, HR:2.26, 95% CI: 1.49~3.42; P=0.008, HR:0.91, 95% CI: 0.85~0.98, respectively), whereas hypertension was associated with late recurrence (P=0.001, HR:3.48, 95% CI: 1.34~9.07). Conclusion RFCA is an effective strategy in elimination of RVOT VAs. However, early and late recurrences occur commonly. Patients with early and late VA recurrences demonstrated non-uniform patterns of clinical characteristics and electrophysiological properties.
    Heart Rhythm. 01/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background The implantation of permanent pacemaker (PPM) is life-saving for patients with life-threatening bradycardia. However, the effectiveness and prognosis of PPM implantations for extremely old patients (> 90 years old) have not been investigated before. Methods From 2001-2012, a total of 108 patients older than 90 years were identified from 2,630 consecutive patients receiving PPM implantations in our hospital as the study group. For each study patient, four age-, gender- and comorbidity-matched subjects who did not have the diagnoses of bradyarrhythmias indicated for PPM implantations were selected from the “Taiwan National Health Research Database” to constitute the control group (n = 432). The study endpoint was all-cause mortality. Results The median age of the study population was 91 (inter-quartile range = 90-93) years. Among the PPM group, 45 patients died during the follow-up with an annual mortality rate of 18.7%. The risk of mortality did not differ significantly between the study and control groups with a hazard ratio of 1.020 (95% confidence interval = 0.724-1.437, p value = 0.912) after the adjustment for age and gender. Procedure-related complications occurred in 7.4% of the patients receiving PPM implants, and pocket hematoma was the most common one. The pre-implantation history of heart failure and cerebrovascular accident, rather than age, were significant predictors of mortality among PPM recipients. Conclusions Nonagenarians with severe bradyarrhythmias could retain the same life expectancies as those without bradyarrhythmias through PPM implantations. Extremely old age (> 90 years) should not be a barrier for PPM implants when indications were present.
    The Canadian journal of cardiology 01/2014; · 3.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: It is unclear whether atrial fibrillation (AF) adversely influences the clinical course of patients with hepatocellular carcinoma (HCC). During the period from January 1, 2001 to December 31, 2010, 476 patients (mean ± SD age 60.3 ± 12.9 years) diagnosed with HCC were retrospectively enrolled in our study. The HCC stage, treatment, baseline characteristics, underlying cardiovascular diseases, and corresponding drug treatment were systematically reviewed. The primary endpoint was death from any cause. AF was associated with a significantly reduced survival time in patients with HCC (AF vs. non-AF patients mean ± SD survival time 470.1 ± 89.6 days vs. 1161.2 ± 32.6 days, log-rank p < 0.001; probability of survival 0.20, 95% confidence interval 0.10-0.38, p < 0.001). After adjustment for gender and age, AF was still associated with poorer survival times (hazard ratio 4.131, 95% confidence interval 2.134-5.733, p < 0.001). The causes of death among 22 patients with both HCC and AF included 11 cases of hepatic failure, four cases of ruptured tumor, and two cases of bleeding from esophageal varices. None of these patients with AF used warfarin. Seven bleeding events related to HCC were noted, but none of these patients developed a major thromboembolism. The mean ± SD follow-up period was 645 ± 468 days. Patients with HCC had a significantly reduced survival time with the comorbidity of AF. Tumor rupture was relatively common among patients with both HCC and AF. The anticoagulation treatment of AF in patients with HCC deviated from the current guidelines without an increase in thromboembolic events.
    Journal of the Chinese Medical Association 12/2013; · 0.75 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Antitachycardia pacing (ATP), a quick, painless and effective therapy available in implantable cardioverter-defibrillators (ICDs), can terminate most, but not all, sustained ventricular tachycardias (VTs). This study investigated the possible ventricular electrogram (EGM) factors for predicting the effectiveness of ATP therapy from ICD recordings. In this study we analyzed 113 EGMs of VT episodes acquired from 20 patients who received ATP or shock to terminate tachyarrhythmias during follow-up after ICD implantations. The relationship between the outcome of ATP and VT EGM features (such as voltage, width, cycle length, and beat-to-beat morphologic variation) was investigated. The divergence (beat-to-beat morphologic variation) of the VT EGMs was determined by calculating the total deviation of all EGMs away from the average template after all VT EMGs were aligned. In total, 72 (63.7%) successful (Group I) and 41 (36.3%) unsuccessful (Group II) ATP therapy episodes were analyzed. The mean amplitude, cycle length, and EGM width were similar between these two groups (P>0.05). A multivariate analysis demonstrated that the only predictor of successful ATP was the divergence among the VT EGMs (0.56±0.32 vs. 1.07±0.64, P<0.001, for Groups 1 and 2, respectively). The optimal cut-off value for determining a successful ATP therapy was 0.73 (with an area under the curve of 0.769, sensitivity of 81.9% [95% CI = 71.1-90.0], and specificity of 65.9% [95% CI = 49.4-79.9], P<0.0001). Signal analyses from stored EGMs of VT can predict the response of ATP therapy in patients with ICD implantations. A lesser ventricular beat-to-beat morphologic variation in the intracardiac recordings from ICDs correlated with a higher probability of a successful ATP. This article is protected by copyright. All rights reserved.
    Journal of Cardiovascular Electrophysiology 12/2013; · 3.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although hyperuricemia has been reported to be a risk factor of stroke, the relationship between hyperuricemia and stroke in patients with atrial fibrillation (AF) remains uncertain. The goal of the present study was to investigate whether hyperuricemia could potentially refine clinical risk stratification in AF. This study used the "National Health Insurance Research Database" in Taiwan. A total of 7601 AF patients who did not receive antiplatelet agents or oral anticoagulants were identified as the study population. Hyperuricemia was defined as having at least one episode of gout attack necessitating long-term treatment with uric acid-lowering agents. The association between hyperuricemia and ischemic stroke was analyzed. During the follow up of 3.0±2.7years, 1116 patients (14.7%) experienced ischemic stroke with an annual rate of around 4.9%. Hyperuricemia significantly predicts stroke, with a hazard ratio (HR) of 1.280 after adjusting for CHA2DS2-VASc score and other comorbidities. Among the 376 patients with a CHA2DS2VASc score of 0, hyperuricemia can further stratify them into 2 groups with different stroke rates (7.1% versus 1.3%, p=0.020). The adjusted HR of hyperuricemia in predicting ischemic stroke diminished from 7.491 for patients with a CHA2DS2-VASc score of 0 to 1.659 for those with a score of 3, and became insignificant for patients with a score ≥4. Hyperuricemia was a significant risk factor of stroke which could potentially refine the clinical risk stratification in AF. It deserves a prospective trial to investigate whether it would change the current strategy for stroke preventions using oral anticoagulants.
    International journal of cardiology 11/2013; · 6.18 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sudden cardiac death (SCD) is the most catastrophic presentation in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C). We aimed to investigate the seasonal variations in the frequency of SCD and ventricular tachyarrhythmia in patients with AVRD/C, and to elucidate the meteorological factors that trigger these events. From 1998 to 2012, we enrolled 88 consecutive ARVD/C patients from Taipei City. The cohort included 20 living patients who received implantable cardioverter defibrillator (ICD) and 68 autopsied patients with SCD from the National Forensic Institute Registry. The baseline clinical characteristics, seasonal distribution, and associated meteorological factors were explored to predict the occurrences of events, which include appropriate ICD interventions and SCD. There were 106 events, including 38 appropriate ICD interventions (35.8%, 1.9 episodes per patient) in ARVD/C living patients and 68 SCD (64.2%). The seasonal peak occurred predominantly in the summer (P<0.05) in both groups. For meteorological factors, the onset of event was associated with higher mean daily temperature and longer sunshine duration. Variation of humidity within 3 days of events was significantly increased. After multivariate logistic regression analysis, higher average daily temperature and larger variation of humidity were associated with increase in events (P<0.001, odd ratio [OR]: 1.23, 95% confidence interval [CI]: 1.16~1.31; P<0.001, OR: 1.19, 95% CI: 1.15~1.23, respectively). There was seasonal variation with a summer peak in the occurrence of ventricular arrhythmias and SCD in patients with ARVD/C. Meteorological factors including higher temperature and larger variation of humidity within 3 days of events were independently associated with the development of events.
    Heart rhythm: the official journal of the Heart Rhythm Society 09/2013; · 4.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although hyperuricemia was associated with several cardiovascular diseases, the role of uric acid (UA) in left atrial (LA) remodeling and new-onset atrial fibrillation (AF) has not been fully explored. The goal of the present study is to investigate the relationship between UA, LA diameter and the development of AF in the large-scale cohort. The study consisted of 2 parts. First, we investigated the association between serum UA and LA diameter in a single-center database (n=3043). Second, we studied and compared the risk of new-onset AF among patients with and without hyperuricemia in the nationwide longitudinal cohort in Taiwan (n=122,524). Elevated serum level of UA was associated with an increased systemic inflammation, and insulin resistance. The LA diameter was significantly correlated with serum UA (r=0.341, p value<0.001). The linear correlation between LA dimension and UA level remained significant after the adjustment for clinical, biochemical and echocardiographic variables. In the nationwide cohort, there were 2339 patients (1.9% of the study population) developing AF during the follow-up of 6.3±3.0years. The AF occurrence rate was higher in patients with hyperuricemia than those without it (2.1% versus 1.7%; p value<0.001). Hyperuricemia was a significant risk factor of new-onset AF with a hazard ratio of 1.191 (95% confidence interval=1.098-1.292, p value<0.001) in the multivariate Cox regression analysis. Hyperuricemia was associated with a larger LA size and may be a novel risk factor for the development of AF.
    International journal of cardiology 07/2013; · 6.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A length polymorphism of GT repeats in the promoter region of the human heme oxygenase-1 (HO-1) gene modulates its gene transcription to protect against myocardial injury. The present study investigated the association between HO-1 promoter polymorphisms and the outcomes of catheter ablation of atrial fibrillation (AF). The allelic frequencies of GT repeats in the HO-1 gene promoter were screened in 205 random individuals who underwent catheter ablation for drug refractory AF.In the patients who received catheter ablation, those with AF recurrence had fewer GT repeats (53.4±7.1 vs. 56.1±6.5, p = 0.004), a lower incidence of hyperlipidemia, more non-paroxysmal AF, and a larger left atrial diameter. After conducting a multivariate logistic analysis, the number of GT repeats (Odds ratio: 0.94, 95% CI 0.90-0.99, p = 0.01) and the diameter of the left atrium (Odds ratio: 1.08, 95% CI 1.02-1.15, p = 0.01) remained independent predictors. The carriers of GT repeats, which were <29 in both alleles, were associated with a lower sinus maintenance rate after catheter ablation (38.5% vs. 60.1%, p = 0.003). The patients were divided into paroxysmal and non-paroxysmal AF groups; the number of GT repeats was associated with AF recurrence only in the patients with paroxysmal AF. The number of GT repeats, combined with LAD, was significant for predicting AF recurrence after catheter ablation (p = 0.01). The number of GT repeats was not found to be associated with differences in the left atrial diameter, the biatrial voltage, or the levels of bilirubin, ferritin, iron, C-reactive protein, or von-Willibrand factor. In conclusions, HO-1 gene promoter polymorphisms were associated with AF recurrence after catheter ablation.
    PLoS ONE 01/2013; 8(2):e56440. · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Elevated plasma levels of asymmetric dimethylarginine (ADMA) have been reported to be associated with endothelial dysfunction, inflammation, and oxidative stress in multiple cardiovascular diseases. This study aimed to investigate whether ADMA was a predictor of clinical outcomes in atrial fibrillation (AF). From 2006-2009, 990 individuals were referred to our institution for coronary angiography. Among these patients, 141 subjects with a diagnosis of AF, including 52 paroxysmal AF (PAF) and 89 non-paroxysmal AF (non-PAF) patients, were identified as the study population. Plasma ADMA levels were measured. An adverse event was defined as the occurrence of ischemic stroke or cardiovascular death. The ADMA levels were higher in AF than non-AF patients (0.50±0.13 versus 0.45±0.07 µmol/L; p<0.001). Besides, non-PAF patients had higher ADMA levels than PAF patients (0.52±0.15 versus 0.48±0.08 µmol/L; p<0.001). During the follow-up of 30.7±14.4 months, 21 patients (14.9%) experienced adverse events, including cardiovascular death in 7 patients and ischemic stroke in 14. ADMA level, CHA2DS2-VASc score, and left atrial diameter were independent predictors of adverse events in the multivariate analysis. At a cutoff-value of 0.55 µmol/L, the Kaplan-Meier survival analysis showed that patients with a high ADMA level had a higher event rate during the follow-up period. A higher level of ADMA was a risk factor of adverse events in AF patients, which was independent from the CHA2DS2-VASc score. It deserves to further study whether ADMA could potentially refine the clinical risk stratification in AF.
    PLoS ONE 01/2013; 8(8):e71675. · 3.53 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Epicardial fat was closely related to atrial fibrillation (AF). Transthoracic echocardiography (TTE) has been proposed to be a convenient imaging tool in assessing epicardial adipose tissue (EAT). The goal of the present study was to investigate whether the EAT thickness measured on TTE was a useful parameter in predicting procedural outcomes of AF ablations. A total of 227 paroxysmal AF (PAF) and 56 non-paroxysmal AF (non-PAF) patients receiving catheter ablations from 2008-2010 were enrolled. Echocardiography-derived regional EAT thickness from parasternal long-axis view was quantified for each patient. Free of recurrence was defined as the absence of atrial arrhythmias without using antiarrhythmic agents after ablations. The mean EAT thickness of the study population was 6.1 ± 0.8 mm. Non-PAF patients had a thicker EAT than that of PAF patients (7.0 ± 0.7 mm versus 5.9 ± 0.7 mm, p value <0.001). During the follow-up of 16 ± 9 months, there were 95 patients (33.6%) suffering from recurrences of atrial arrhythmias. Non-PAF, chads2 score, left atrial diameter and EAT thickness were independent predictors of recurrence after catheter ablations. At a cutoff value of 6 mm for PAF and 6.9 mm for non-PAF, the measurement of EAT thickness could help us to identify patients at risk of recurrences. EAT thickness may serve as a useful parameter in predicting recurrences after AF ablations. Compared to other imaging modalities, TTE can be an alternative choice with less cost and time in assessing the effects of EAT on ablation outcomes.
    PLoS ONE 01/2013; 8(9):e74926. · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: The components of CHADS(2) score were reported to be important risk factors for the development of atrial fibrillation (AF). The goal of the current study was to investigate whether the CHADS(2) score was a useful scheme in predicting new-onset AF. Furthermore, we aimed to use the CHADS(2) scoring system to estimate the individual risk in developing AF for patients with different comorbidities. METHODS: From January 1, 2000 to December 31, 2001, a total of 702,502 patients older than 18years old and who had no history of cardiac arrhythmias were identified from the "National Health Insurance Research Database" released by the Taiwan National Health Research Institutes. The CHADS(2) score was calculated for every patient. Finally, 628,807 (score 0), 47,039 (score 1), 15,655 (score 2), 6843 (score 3), 3315 (score 4), 790 (score 5) and 53 (score 6) patients were studied and followed for the occurrences of AF. RESULTS: During a follow-up of 9.0±2.2years, there were 9187 (1.3%) patients experiencing new-onset AF. The incidence of AF was 1.5 per 1000 patient-years. The incidence increased from 0.8 per 1000 patient-years for patients with a CHADS(2) score of 0 to 34.6 per 1000 patient-years for those with a CHADS(2) score of 6. After an adjustment for the gender and comorbidities, the hazard ratio (95% confidence interval) of each increment of the CHADS(2) score in predicting AF was 2.342 (2.309-2.375; p<0.001). CONCLUSIONS: The CHADS(2) score, consisting of an age >75 and several clinical risk factors was useful in risk estimation and stratification of new-onset AF.
    International journal of cardiology 12/2012; · 6.18 Impact Factor

Publication Stats

633 Citations
318.30 Total Impact Points

Institutions

  • 2007–2014
    • Taipei Veterans General Hospital
      • Cardiology Division
      T’ai-pei, Taipei, Taiwan
  • 2003–2014
    • National Yang Ming University
      • • School of Medicine
      • • Institute of Clinical Medicine
      T’ai-pei, Taipei, Taiwan
  • 2010
    • Taipei City Hospital
      T’ai-pei, Taipei, Taiwan
    • Cathay General Hospital
      T’ai-pei, Taipei, Taiwan
  • 2008
    • Taichung Veterans General Hospital
      臺中市, Taiwan, Taiwan
  • 2005
    • Wan Fang Hospital
      T’ai-pei, Taipei, Taiwan